TSS
CMMB

Two Sigma Securities’s Chemomab Therapeutics CMMB Stock Holding History

Two Sigma Securities’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,526
Closed -$24.1K – 1581
2025
Q1 		$24.1K Buy
+5,526
New +$38.8K ﹤0.01% 1075
2024
Q4 		– Sell
-9,985
Closed -$62.7K – 1911
2024
Q3 		$62.7K Buy
+9,985
New +$56K ﹤0.01% 2346
2024
Q2 		– Sell
-6,546
Closed -$20.4K – 3058
2024
Q1 		$20.4K Buy
+6,546
New +$16.9K ﹤0.01% 2672

Other funds holding CMMB

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $527M AUM 50.16% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Securities's CMMB Position: Q2 2025 in Review

Two Sigma Securities sold out of Chemomab Therapeutics (CMMB) in Q2 2025, closing a stake of 5,526 shares — an estimated $24.1K sold.

Two Sigma Securities first reported a position in CMMB in Q1 2024 and held it in 3 quarters. The position peaked at $62.7K in Q3 2024. 14 funds tracked by Wall St. Rank hold CMMB as of Q2 2025.

  • Two Sigma Securities reported no remaining Chemomab Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Securities sold 5,526 Chemomab Therapeutics shares in Q2 2025, an estimated $24.1K.
  • Two Sigma Securities first reported a position in Chemomab Therapeutics in Q1 2024 and held it in 3 quarters.
  • Two Sigma Securities's Chemomab Therapeutics position peaked at $62.7K in Q3 2024.
  • 14 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.